These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

642 related articles for article (PubMed ID: 26541516)

  • 21. Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.
    Gu S; Mu Y; Zhai S; Zeng Y; Zhen X; Dong H
    PLoS One; 2016; 11(11):e0165629. PubMed ID: 27806087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Chien CL; Chen YC; Malone DC; Peng YL; Ko Y
    Curr Med Res Opin; 2020 Oct; 36(10):1619-1626. PubMed ID: 32851879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.
    Liao CT; Yang CT; Toh HS; Chang WT; Chang HY; Kuo FH; Lee MC; Hua YM; Tang HJ; Strong C; Ou HT
    Cardiovasc Diabetol; 2021 Oct; 20(1):204. PubMed ID: 34627231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes.
    Chin KL; Ofori-Asenso R; Si S; Hird TR; Magliano DJ; Zoungas S; Liew D
    Sci Rep; 2019 Mar; 9(1):3256. PubMed ID: 30824788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of Empagliflozin Compared with Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus and Established Cardiovascular Disease in Greece.
    Gourzoulidis G; Tzanetakos C; Ioannidis I; Tsimihodimos V; Diogo V; Karpouzos G; Papageorgiou G; Kourlaba G
    Clin Drug Investig; 2021 Apr; 41(4):371-380. PubMed ID: 33687695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
    Johnston R; Uthman O; Cummins E; Clar C; Royle P; Colquitt J; Tan BK; Clegg A; Shantikumar S; Court R; O'Hare JP; McGrane D; Holt T; Waugh N
    Health Technol Assess; 2017 Jan; 21(2):1-218. PubMed ID: 28105986
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness of Dipeptidylpeptidase-4 Inhibitors Added to Metformin in Patients With Type 2 Diabetes in China.
    Lin WQ; Cai ZJ; Chen T; Liu MB; Li N; Zheng B
    Front Endocrinol (Lausanne); 2021; 12():684960. PubMed ID: 34484112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of saxagliptin vs glimepiride as a second-line therapy added to metformin in Type 2 diabetes in China.
    Gu S; Deng J; Shi L; Mu Y; Dong H
    J Med Econ; 2015; 18(10):808-20. PubMed ID: 25950193
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.
    Ku EJ; Lee DH; Jeon HJ; Oh TK
    Diabetes Res Clin Pract; 2019 May; 151():65-73. PubMed ID: 30954510
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
    Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
    J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.
    Asche CV; Hippler SE; Eurich DT
    Pharmacoeconomics; 2014 Jan; 32(1):15-27. PubMed ID: 24357160
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland.
    Grzeszczak W; Czupryniak L; Kolasa K; Sciborski C; Lomon ID; McEwan P
    Diabetes Technol Ther; 2012 Jan; 14(1):65-73. PubMed ID: 22066527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes.
    Guzauskas GF; Rind DM; Fazioli K; Chapman RH; Pearson SD; Hansen RN
    J Manag Care Spec Pharm; 2021 Apr; 27(4):455-468. PubMed ID: 33769850
    [No Abstract]   [Full Text] [Related]  

  • 34. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy.
    Schwarz B; Gouveia M; Chen J; Nocea G; Jameson K; Cook J; Krishnarajah G; Alemao E; Yin D; Sintonen H
    Diabetes Obes Metab; 2008 Jun; 10 Suppl 1():43-55. PubMed ID: 18435673
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.
    Klarenbach S; Cameron C; Singh S; Ur E
    CMAJ; 2011 Nov; 183(16):E1213-20. PubMed ID: 21969406
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study.
    Escobar C; Morales C; Capel M; Simón S; Pérez-Alcántara F; Pomares E
    BMC Health Serv Res; 2022 Feb; 22(1):217. PubMed ID: 35177053
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin.
    Gorgojo-Martínez JJ; Malkin SJP; Martín V; Hallén N; Hunt B
    J Med Econ; 2020 Feb; 23(2):193-203. PubMed ID: 31613199
    [No Abstract]   [Full Text] [Related]  

  • 38. Efficacy and safety of dapagliflozin plus saxagliptin vs monotherapy as added to metformin in patients with type 2 diabetes: A meta-analysis.
    Zhuang Y; Song J; Ying M; Li M
    Medicine (Baltimore); 2020 Jul; 99(30):e21409. PubMed ID: 32791755
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Utility Analysis of Dapagliflozin Versus Saxagliptin Treatment as Monotherapy or Combination Therapy as Add-on to Metformin for Treating Type 2 Diabetes Mellitus.
    Hu S; Deng X; Ma Y; Li Z; Wang Y; Wang Y
    Appl Health Econ Health Policy; 2021 Jan; 19(1):69-79. PubMed ID: 32783086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.
    Pawaskar M; Bilir SP; Kowal S; Gonzalez C; Rajpathak S; Davies G
    Diabetes Obes Metab; 2019 Apr; 21(4):1010-1017. PubMed ID: 30565386
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.